An antibody raised against Golgi apparatus protein 1 (GLG1); also known as E-selectin ligand-1 (ESL-1), it is a golgi apparatus-localized protein which acts in osteoblasts to regulate bone homeostasis.
Catalogue number crb2005704 Antibody Anti-GLG1 antibody Antigen Peptide KLH conjugated synthetic peptide crb1200913 Protein ID UniProtKB - Q92896 Aliases Golgi apparatus protein 1, Cysteine-rich fibroblast growth factor receptor, CFR-1, E-selectin ligand 1, ESL-1, Golgi sialoglycoprotein MG-160, GLG1, CFR1, ESL1, MG160 Cross-Reactivity Human, Mouse, Rat Host Species Rabbit Antibody Type Polyclonal Concentration 1 mg/ml Glycine (R1G), 1 mg/ml Glycine (R2G), 0.5 mg/ml TEA (R2T) Target GLG1 Storage This material is supplied in PBS containing 0.01% sodium azide and 1% trehalose. The product should be stored at +4°C for short term storage and -20°C for long term storage. Avoid repeated freeze/thaw cycles.
GLG1 as an important regulator of bone remodelling which localises to the Golgi apparatus. It functions to maintain a balanced bone homeostasis where it can play either a catabolic or anabolic role. GLG1 regulates TGF-β maturation during cartilage homeostasis. GLG1 is also a novel adiponectin (APN)-binding protein. APN is an adipocyte-derived bioactive molecule with anti-diabetic and anti-atherogenic properties. GLG1 is also a novel polysialic acid (polySia) acceptor. PolySia is a protein-modifying glycan implicated in modulating microglia activity.
GLG1 acts in the initial process to tether leukocytes to vascular endothelium however, this role has been implicated in the method tumour cells are able to progress and migrate. GLG1 has also been linked to the Lou Gehrig’s disease also known as Amyotrophic Lateral Sclerosis 1 (ALS1).